Agilent Technologies is a global leader in providing scientific instruments, software, and services for laboratories in the life sciences, diagnostics, and applied chemical markets. The company specializes in developing innovative solutions that enable scientists and researchers to enhance their workflows, improve productivity, and achieve more accurate results across various applications, including pharmaceuticals, environmental testing, and food safety. Agilent’s commitment to advancing science is reflected in its extensive portfolio of cutting-edge technologies and collaborative approach to supporting customers in their quest for discovery and innovation. Read More
Agilent Technologies Inc. (NYSE: A) today announced that its MMR IHC Panel pharmDx (Dako Omnis) has received class C companion diagnostic (CDx) certification under EU in vitro diagnostic regulation (IVDR)1 as a CDx test for colorectal cancer. MMR IHC Panel pharmDx (Dako Omnis) is indicated as an aid to identify mismatch repair (MMR) deficient CRC patients eligible for treatment with OPDIVO® (nivolumab) in combination with YERVOY® (ipilimumab). MMR IHC Panel pharmDx (Dako Omnis) is approved for exclusive use with the Agilent Dako Omnis automated staining solution.
Shares of life sciences tools company Agilent Technologies (NYSE:A)
jumped 3.7% in the morning session after the company reported better-than-expected revenue in its second-quarter 2025 results and provided strong guidance for the upcoming quarter. For the quarter, the company announced revenue of $1.74 billion, up 10.1% year on year, surpassing analysts' expectations of $1.67 billion. Its adjusted earnings per share of $1.37 met consensus estimates. Looking ahead, Agilent's revenue guidance for the third quarter was a key positive, with its forecast of $1.83 billion at the midpoint coming in comfortably above Wall Street's projections of $1.77 billion. The strong top-line performance and optimistic near-term outlook appeared to drive investor confidence.
Stay informed about the performance of the S&P500 index in the middle of the day on Thursday. Uncover the top gainers and losers in today's session for valuable insights.
Life sciences tools company Agilent Technologies (NYSE:A) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 10.1% year on year to $1.74 billion. On top of that, next quarter’s revenue guidance ($1.83 billion at the midpoint) was surprisingly good and 3.4% above what analysts were expecting. Its non-GAAP profit of $1.37 per share was in line with analysts’ consensus estimates.
Life sciences tools company Agilent Technologies (NYSE:A) announced better-than-expected revenue in Q2 CY2025, with sales up 10.1% year on year to $1.74 billion. On top of that, next quarter’s revenue guidance ($1.83 billion at the midpoint) was surprisingly good and 3.4% above what analysts were expecting. Its non-GAAP profit of $1.37 per share was in line with analysts’ consensus estimates.
Agilent (A) beat Q3 FY25 revenue estimates with $1.74B but slightly missed on EPS. The company posted strong growth across all segments and provided optimistic full-year guidance.
Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.74 billion for the third quarter ended July 31, 2025, exceeding revenue guidance and representing growth of 10.1% reported and up 6.1% core(1) compared with the third quarter of 2024.
Wall Street traded cautiously on Wednesday, with major indices little changed at midday as investors awaited NVIDIA Corp.‘s (NASDAQ:NVDA) second-quarter earnings after the bell.
CUMMING, GA - August 26, 2025 ( NEWMEDIAWIRE ) - Metavesco, Inc. (OTC: MVCO), a publicly traded diversified holding company, today announced the release of its position paper, “Tokenizing the OTC: A Vision for Transparency, Liquidity, and Growth.” The white paper outlines Metavesco’s proposed framework for bringing OTC equities on-chain, with the goal of unlocking global liquidity and reducing structural barriers for small public companies.
Shares of life sciences tools company Agilent Technologies (NYSE:A)
jumped 3.7% in the afternoon session after Federal Reserve Chair Jerome Powell indicated that interest rates could be cut, lifting stocks across sectors. The positive sentiment swept through Wall Street, with major indices like the Dow Jones Industrial Average, S&P 500, and Nasdaq all posting significant gains. Federal Reserve Chair Jerome Powell's comments eased investor concerns, raising hopes for a less restrictive monetary policy which can stimulate economic activity.
Agilent Technologies Inc. (NYSE: A) today announced that President and CEO Padraig McDonnell will participate in a fireside chat at this year’s Wells Fargo Healthcare Conference.
Agilent Technologies Inc. (NYSE: A) today announced that its MMR IHC Panel pharmDx (Dako Omnis) has received FDA approval as a companion diagnostic (CDx) test for colorectal cancer. This test aids in identifying mismatch repair deficient (dMMR) colorectal cancer (CRC) patients who are eligible for treatment with Bristol Myers Squibb’s Opdivo® (nivolumab) alone or Opdivo (nivolumab) in combination with Yervoy® (ipilimumab). The MMR IHC Panel pharmDx (Dako Omnis) is approved for exclusive use with the Agilent Dako Omnis automated staining solution.
Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors.
However, their sheer size makes it more challenging to maintain high growth rates as they’ve already captured significant portions of their markets.
Agilent Technologies Inc. and Georgia Tech today announced the establishment of an Agilent Center of Excellence (CoE) for Environmental Health and Engineering to advance research in environmental sustainability, water recycling, and biologics.
Agilent Technologies Inc. (NYSE: A) today announced the introduction of its Dako Omnis family of instruments with three new models—Agilent Dako Omnis 110, 165, and 165 Duo—designed to meet the evolving needs of pathology laboratories of all sizes. These new instruments provide labs with the flexibility to tailor their staining solutions according to volume, workflow, and diagnostic requirements.
